Results 181 to 190 of about 430,365 (280)

Evolutionary radiation of large‐bodied gorgonopsians from the lower Abrahamskraal formation of South Africa

The Anatomical Record, EarlyView.
Abstract The middle Permian represents a critical interval in therapsid evolution, when gorgonopsians emerged as some of the first specialized apex predators within terrestrial ecosystems. Despite their significance, the early diversification of Gorgonopsia in Gondwana remains poorly understood due to scarcity and fragmentary material.
Zanildo Macungo, Ricardo Araújo, Bruce S. Rubidge, Michael O. Day, Kathleen N. Dollman, Julien Benoit   +5 more
wiley   +1 more source

Categorical Data in the Evaluation of School-Based Cyberbullying Prevention Programs: A Review of the Literature. [PDF]

Behav Sci (Basel)
Antivilo-Bruna A, Patino-Alonso C.
europepmc   +1 more source

Compensation Response to Hepatic Gluconeogenesis via β‐Hydroxybutyrylation of FBP1 and PCK1 in Dairy Cows

Animal Research and One Health, EarlyView.
(1) Kbhb modification of FBP1 and PCK1 is involved in regulation of the gluconeogenesis pathway. (2) Kbhb of FBP1 and PCK1 is catalyzed by p300 and removed by HDACs. (3) BHB induced an increase in the enzymatic activity of FBP1 and PCK1 through Kbhb modification at the K43 site of FBP1 and the K191 site of PCK1.
DingPing Feng, GuoYan Wang, YuanYuan Zhu, YiNing Zheng, JunHu Yao, Lei Chen, Lu Deng   +6 more
wiley   +1 more source

Visualization for Departures from Symmetry with the Power-Divergence-Type Measure in Square Contingency Tables. [PDF]

Psychometrika
Urasaki W, Nakagawa T, Tsuchida J, Tahata K.   +3 more
europepmc   +1 more source

Use of Clotrimazole in Finfish Aquaculture: Mechanistic Insights, Limitations, and Future Directions for Antifungal Therapy

Animal Research and One Health, EarlyView.
This review critically evaluates clotrimazole as a potential antifungal for finfish aquaculture, highlighting strong mechanistic and in vitro efficacy against aquatic mycoses alongside major gaps in in vivo evidence, toxicokinetics, residue safety, and environmental risk, outlining priorities for responsible therapeutic development and regulatory ...
Arya Sen, Debashri Mondal, Thangapalam Jawahar Abraham   +2 more
wiley   +1 more source

Conflict resolution dynamics with stable caregivers confer resilience for youth exposed to early caregiving-related adversity. [PDF]

Dev Psychopathol
Somers JA, Querdasi FR, Xu S, Aghajani M, Sun QC, Li WL, Nussbaum S, Chu KA, Gancz N, Towner E, Callaghan BL.   +10 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

Concurrent alcohol and smoking use among American Indian and Alaska Native adults participating in a contingency management clinical trial for alcohol use disorder. [PDF]

Front Public Health
Jansen KJ, Puzia M, Herron JL, Lyons AJ, McDonell M, Hirchak K, HONOR Study Team.   +6 more
europepmc   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Breathing in the Dark: Lessons from the April 2025 Blackout for Electricity-dependent Respiratory Patients. [PDF]

Open Respir Arch
Díaz Lobato S, Mayoralas Alises S.
europepmc   +1 more source